Latest News

  • Home
  • Amneal Beats Dr. Reddy’s In Race For A Billion-Dollar Drug
Amneal Beats Dr. Reddy’s In Race For A Billion-Dollar Drug
Wednesday, December 18, 2019 IST
Amneal Beats Dr. Reddy’s In Race For A Billion-Dollar Drug

Amneal Pharmaceuticals Inc. has pipped Dr. Reddy’s Laboratories Ltd. to launch the first generic of a vaginal ring to prevent pregnancy in the U.S., one of the largest markets for most Indian drugmakers.

 
 

The NYSE-listed drugmaker received an abbreviated new drug application approval from the U.S. Food and Drug Administration for EluRyng, the first generic version of Merck & Co.’s NuvaRing, according to a media statement.
 
The New Jersey-based company said it initiated commercialisation activities for the drug, which is being manufactured internally and launching on Dec. 12. Shares of Amneal Pharma surged 33 percent, the most in five months, on the New York Stock Exchange after the announcement.
 
NuvaRing’s annual sales in the U.S. stood at nearly $976 million for the 12 months ended Oct. 31, according to IQVIA, a healthcare data and analytics provider. The drug at present doesn’t have any approved generic in the U.S. Teva Pharmaceutical Industries Ltd., Mayne Pharma Group Ltd. and Dr. Reddy’s are other drugmakers that have applied to the U.S. FDA to make the copycat version for the American market.
 
In August, Dr. Reddy’s said it received a complete response letter from the U.S. health regulator for its generic version of NuvaRing and was preparing for a response. Initially, the Indian company had scheduled to launch the drug in the first six months of calendar year 2019 but that, according to the company after the second-quarter earnings, got delayed by 10-12 months because of the U.S. FDA letter. Erez Israeli, chief executive officer of Dr. Reddy’s, had said during the post-earnings conference call that he expected the drug to be launched in the financial year ending March 2021.
 
Dr. Reddy’s has yet to respond to BloombergQuint’s emailed queries.
 
Acknowledging the risk of a competitor launching the drug first, Girish Bakhru, pharma analyst at Bank of America Merrill Lynch, estimated NuvaRing to generate sales worth $50 million in FY21 and FY22 each for Dr. Reddy’s.
 
SBICAP Securities, in its latest report, said the drug is estimated to contribute $100 million to the company’s top line through FY23.
 
Prashant Nair, pharma analyst at Citi Research, said a launch before mid-2020 was unlikely and any further delay couldn’t be ruled out. Nair expects Dr. Reddy’s to launch the generic in the second half of the next calendar year as opposed to the first quarter forecast earlier.
 
Dr. Reddy’s other competitor Mayne Pharma, in a post-earnings conference call, said its approval was delayed. Teva said it expected an approval later this year.

 
 

 
 
 
 
 

Related Topics

 
 
 

Trending News & Articles

 

More in

 Article
Veteran actress Nimmi dies at 88 in Mumbai

Yesteryear actress Nimmi breathed her last on Wednesday evening in Mumbai. She was 88 years old.

Recently posted. 530 views . 0 min read
 

 Article
Akshay Kumar is angry and all about business on new Gold poster

Akshay Kumar plays a Bengali hockey player in Reema Kagti’s Gold, and the makers insist it is a fictional story.

Recently posted. 643 views . 0 min read
 

 Article
Bigg Boss 13 Winner Sidharth Shukla Passes Away After Suffering Heart Attack

Sidharth Shukla began his career in showbiz as a model and made his acting debut with a lead role in the television show "Babul Ka Aangann Chootey Na".

Recently posted. 582 views . 1 min read
 

 Video
If Rivers Could Revolt



Recently posted . 1K views
 

 Article
Tiger Shroff opens up about the friendship between him and Disha Patani

Though rumoured couple Tiger Shroff and Disha Patani have denied about their alleged relationship, the pair is often spotted together at various occasions. Recent...

Recently posted. 585 views . 1 min read
 

 Article
Exclusive: Man attacking Tanushree in viral-video breaks his silence

On Monday, a video went viral on social media which showed the horror unleashed on Tanushree Dutta on the sets of 'Horn Ok Pleasss' in 2008.

Recently posted. 687 views . 1 min read
 

 
 
 

   Prashnavali

  Thought of the Day

The price of success is hard work, dedication to the job at hand, and the determination that whether we win or lose, we have applied the best of ourselves to the task at hand.
Vince Lombardi

Be the first one to comment on this story

Close
Post Comment
Shibu Chandran
2 hours ago

Serving political interests in another person's illness is the lowest form of human value. A 70+ y old lady has cancer.

November 28, 2016 05:00 IST
Shibu Chandran
2 hours ago

Serving political interests in another person's illness is the lowest form of human value. A 70+ y old lady has cancer.

November 28, 2016 05:00 IST
Shibu Chandran
2 hours ago

Serving political interests in another person's illness is the lowest form of human value. A 70+ y old lady has cancer.

November 28, 2016 05:00 IST
Shibu Chandran
2 hours ago

Serving political interests in another person's illness is the lowest form of human value. A 70+ y old lady has cancer.

November 28, 2016 05:00 IST


ads
Back To Top